Sodium zirconium cyclosilicate is a Small Molecule owned by AstraZeneca, and is involved in 28 clinical trials, of which 15 were completed, 11 are ongoing, and 2 are planned.

Sodium zirconium cyclosilicate (ZS-9) acts as a cation exchanger that aids in removing significant potassium and urine urea nitrogen. The drug candidate depletes potassium and ammonium ion by binding to them in the presence of other ions (Ca/Mg). It releases sodium ion and hydrogen ion into the gut and absorbs potassium ion and ammonium ion. ZS-9 does not exchange calcium ion or magnesium ion as they are large divalent rather than monovalent ions. It removes phosphate when used with an anion exchanger, thereby allowing the potassium ion to be absorbed back into the body. The drug candidate exhibit therapeutic intervention in the treatment of the disease by exhibiting large potassium absorption capacity.

The revenue for Sodium zirconium cyclosilicate is expected to reach a total of $8.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sodium zirconium cyclosilicate NPV Report.

Sodium zirconium cyclosilicate was originated by ZS Pharma and is currently owned by AstraZeneca.

Sodium zirconium cyclosilicate Overview

Sodium zirconium cyclosilicate (Lokelma) is a selective oral sorbent. It is formulated as powder for suspension for oral route of administration. Lokelma is indicated for the treatment of hyperkalaemia in adults and chronic kidney disease.

Sodium zirconium cyclosilicate (Lokelma) was under development for the treatment of chronic kidney disease, hyperkalemia in Australia, South Korea, and Taiwan. The drug candidate is a non-systemic sorbent which is developed based on ZrSi technology platform.

AstraZeneca Overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.

Quick View – Sodium zirconium cyclosilicate

Report Segments
  • Innovator (NME)
Drug Name
  • Sodium zirconium cyclosilicate
Administration Pathway
  • Oral
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.